Search Results

You are looking at 1 - 10 of 2,919 items for :

  • Refine by Access: All x
Clear All
Full access

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy

Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F. Lennie Wong, Andrew S. Artz, Tanya Siddiqi, Liana Nikolaenko, Jasmine Zain, Matthew Mei, Geoffrey Shouse, Leslie L. Popplewell, Alex F. Herrera, L. Elizabeth Budde, Stephen J. Forman, and Saro H. Armenian

to CAR T-cell therapy is of major clinical importance. Abnormal skeletal muscle measurements at baseline such as low muscle mass and resultant fat infiltration (myosteatosis) have been associated with adverse cancer-related outcomes and all

Full access

Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer

Deepika Kumar, Elad Neeman, Shiyun Zhu, Hongxin Sun, Dinesh Kotak, and Raymond Liu

almost every oncology treatment trial and is known to correlate with toxicities from systemic therapy and patients’ ability to tolerate treatment, quality of life, response to treatment, and various clinical outcomes, such as hospitalizations and

Full access

Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins, and Michael J. Sorich

associated with several adverse outcomes, including increased all-cause mortality, cardiovascular and renal diseases, dementia, infections, fractures, hypomagnesemia, and cancers. 2 , 3 In contrast, in preclinical in vitro studies, PPIs were initially

Full access

Appropriate Use of Nomograms to Guide Prostate Cancer Treatment Selection

Andrew K. Lee and Christopher L. Amling

F or decades physicians have attempted to accurately predict post-treatment outcomes before performing prostate cancer interventions. Use of basic clinical factors, such as clinical T-stage, biopsy Gleason sum, and pretreatment prostate

Full access

Non-Transplant Therapy for Older Adults with Acute Myeloid Leukemia

Mikkael A. Sekeres

.S. Interim projections by age, sex, race, and Hispanic origin . Available at : . Accessed October 19, 2005 . 9. Friedberg JW Neuberg D Stone RM . Outcome in patients with myelodysplastic syndrome

Full access

Understanding Causes of Inferior Outcomes in Adolescents and Young Adults With Cancer

Julie A. Wolfson, Kelly M. Kenzik, Blake Foxworthy, John M. Salsman, Katherine Donahue, Marie Nelson, Mary Beth Littrell, Grant R. Williams, and Jennifer M. Levine

the AYA cancer population, some regions have seen improvements despite persistence of disparities as a whole 10 ; this suggests that as we strive toward additional improvements, it is critical to continue to consider AYA outcomes in the context of

Full access

Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia

Hermioni L. Amonoo, Elizabeth Daskalakis, Emma C. Deary, Monica H. Bodd, Matthew J. Reynolds, Ashley M. Nelson, Richard Newcomb, Tejaswini M. Dhawale, Daniel Yang, Selina M. Luger, Jillian L. Gustin, Andrew Brunner, Amir T. Fathi, Thomas W. LeBlanc, and Areej El-Jawahri

outcomes based on a given context) relies on the availability and utilization of a variety of coping strategies. 16 Although we know that patients with newly diagnosed AML use a variety of coping strategies both in the avoidant and approach-oriented coping

Full access

Association Between Frailty and Time Alive and At Home After Cancer Surgery Among Older Adults: A Population-Based Analysis

Julie Hallet, Bourke Tillman, Jesse Zuckerman, Matthew P. Guttman, Tyler Chesney, Alyson L. Mahar, Wing C. Chan, Natalie Coburn, Barbara Haas, and members of the Recovery after Surgical Therapy for Older adults Research–Cancer (RESTORE-Cancer) Group

essential for older adults. However, there are few data on functional outcomes after cancer surgery, with most studies limited to 6- to 12-month time horizons. 12 – 19 Lack of data regarding these outcomes impacts the accuracy of prognostication and can

Full access

Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes

Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park

moderate recommendation in the ASCO guidelines, 21 , 22 was reported by 1.5% (n=15) of respondents. Long-Term Outcomes in Survivors With Severe Neurotoxicity Comparing respondents reporting high (upper-tertile FACT/GOG-NTX) versus low (lowest-tertile FACT

Full access

Screening Tool Identifies Older Adults With Cancer at Risk for Poor Outcomes

Ryan D. Nipp, Leah L. Thompson, Brandon Temel, Charn-Xin Fuh, Christine Server, Paul S. Kay, Sophia Landay, Daniel E. Lage, Lara Traeger, Erin Scott, Vicki A. Jackson, Nora K. Horick, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel

adults with cancer who may experience poor outcomes. Although older patients with cancer represent an increasing and heterogeneous population with diverse needs, little research has sought to identify those at risk of experiencing high symptom burden or